Cite
HARVARD Citation
Munster, P. et al. (2018). Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. British journal of cancer. 119 (9), pp. 1086-1093. [Online].